Unity Bio (UBX) Revenue & Revenue Breakdown
Unity Bio Revenue Highlights
Unity Bio Revenue by Period
Unity Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $236.00K | -95.07% |
| 2021-12-31 | $4.78M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $1.38M | 100.00% |
| 2016-12-31 | - | - |
Unity Bio generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Unity Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.90M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $-236.00K | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $236.00K | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $4.78M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $105.50M | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $1.38M | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Unity Bio generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Unity Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OVID | Ovid Therapeutics | $391.69M | $169.00K |
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| HRTX | Heron Therapeutics | $127.04M | $46.54M |
| RXRX | Recursion Pharmaceuticals | $44.58M | $13.79M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| EXAI | Exscientia | $24.96M | $5.29M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| ENSC | Ensysce Biosciences | $2.23M | - |
| BXRX | Baudax Bio | $1.27M | - |
| FIXX | Q32 Bio | $1.16M | - |
| EDIT | Editas Medicine | - | - |
| CNTB | Connect Biopharma | - | - |
| PRME | Prime Medicine | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| NXTC | NextCure | - | - |
| NLTX | Neurogene | - | - |
| DRMA | Dermata Therapeutics | - | - |
| UBX | Unity Bio | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
| WINT | Windtree Therapeutics | - | - |
| AVIR | Atea Pharmaceuticals | - | - |
UBX Revenue FAQ
What is Unity Bio’s yearly revenue?
Unity Bio's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $236K, representing a decrease of -95.07% compared to 2021. UBX's yearly revenue for 2021 was $4.78M, representing an increase of 100.00% compared to 2020.
What is Unity Bio’s quarterly revenue?
Unity Bio's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). UBX's quarterly revenue for Q4 2023 was $1.9M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Unity Bio’s revenue growth rate?
Unity Bio's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was 0%.